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Immune complex effects on glomerular eicosanoid production and renal
hemodynamics. We examined the effect of glomerular immune complex
(IC) deposition on glomerular eicosanoid synthesis and the role of the
eicosanoids in glomerular pathophysiology. Rats received daily 10 mg
i.v. injections of native bovine gamma—globulin (NBOG) or cationic
bovine gamma—globulin (CBGG) for 21 days; age—matched controls
were maintained. Immunofluorescence and electron microscopy
showed mesangial deposits of IC in the NBGG group and capillary wall
deposits in the CBGG group, without light or electron microscopic
evidence of leukocyte infiltration. One week after the last antigen dose,
GFR was similar in all three groups, but RPF increased in the rats given
CBGG; (8.37 0.90 vs. control 5.54 0.56 mI/mm, P < 0.05).
Olomerular synthesis of prostaglandin E2 (POE2) and thromboxane B2
(TxB2) was normal in animals that received NBGG. Rats given CBGG
had increased glomerular production of PGE2, (2.23 0.37 vs. control
1.03 0.16 ng/mg glomerular dry wt, P < 0.05) and TxB2 (3.12 0.50
vs. control 0.48 0.07ng/mg glomerular dry wt, P < 0.001). Proteinuria
only developed in the rats given CBGG, 86.6 18 mg/24 hr, which
correlated with glomerular TxA2 synthesis, r = 0.82, P = 0.01. Acute
administration of the TxA2 synthesis inhibitor, UK-38,485, and a TxA2
receptor antagonist, EP-092, to rats given CBGG did not affect GFR or
RPF. The cyclo-oxygenase inhibitor, indomethacin, reduced both GFR
and RPF by up to 40% in CBGG-immunized rats. Oral administration of
UK-38,485 for six days to nephrotic rats did not result in a statistically
significant reduction of proteinuria despite 85% inhibition of glomerular
TxB2. We conclude that cationic antigen induces a glomerular disease
pathologically similar to membranous nephropathy. The increment of
RPF is most probably due to increased glomerular POE2. The increased
TxA2 has no effect on glomerular hemodynamics and probably is not a
component in the pathogenesis of proteinuria.
Glomerular synthesis of eicosanoids is increased in several
models of immune and non-immune glomerular injury. Several
studies have linked changes in glomerular synthetic patterns of
eicosanoids with both toxic and immune injury to the kidney. In
adriamycin nephrosis, a non-immune model of glomerular dis-
ease, a causal relationship between enhanced glomerular syn-
thesis of thromboxane A2 (TxA2) and proteinuria has been
noted [1]. Treatment of adriamycin nephrosis with a thrombox-
ane synthetase inhibitor, UK-38,485, normalized glomerular
TxA2 synthesis and reduced but did not eliminate proteinuria
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[1]. In antibody—mediated glomerular injury (nephrotoxic serum
nephntis; NSN), increments of glomerular TxA2 are responsi-
ble for the acute reductions of renal plasma flow (RPF) and
glomerular filtration rate (GFR) [2]; however, glomerular syn-
thesis of PGE2, a vasodilatory autacoid, increases RPF and
GFR within 24 hours of immune injury [3]. Inhibition of
glomerular TxA2 synthesis in NSN did not prevent or reverse
proteinuria [3]. The presence of infiltrating leukocytes in NSN
obscures the cellular source of increased glomerular prostaglan-
din and thromboxane.
The goals of the present study were: first, to develop a
non-infiltrative model of immune—mediated glomerular disease
in which we could study the response of glomerular eicosanoid
synthesis to immune complexes; and second, to examine the
role of eicosanoids in the pathogenesis and pathophysiology of
glomerular immune injury.
Several laboratories have established non-infiltrative models
of glomerular disease utilizing differently charged antigens,
which resulted in differential localization of immune deposits. It
is well known that the glomerular capillary wall has a net
negative charge due to both sialoglycoproteins and proteogly-
cans [41. The negative charge creates a charge—selective barrier
repelling anionic and attracting cationic molecules. Circulating
antigens and/or antibodies may interact with this barrier, lead-
ing to a deposition of cationic particles in the capillary wall.
Experimental serum sickness models, in the rabbit and mouse,
have established a significant role for electrostatic charge [5—8].
In addition, antibody eluted from kidneys of a munne model of
systemic lupus erythematosus was found to have a higher
isoelectric point than those present within the circulation [9].
Also, in Heymann nephritis, cationic antibodies localized in the
glomerulus better than anionic or neutral antibodies [10]. Fi-
nally, enzymatic removal of the proteoglycan which comprises
the glomerular polyanion prevented the subsequent deposition
of cationic immune complexes within the capillary wall [11].
In view of these observations on the role of electrostatic
charge, we utilized cationic and neutrally charged bovine
gamma globulin to develop a non-infiltrative model of glomer-
ular disease in the rat. Our findings support the conclusion that
in non-infiltrative immune complex glomerulonephritis, glomer-
ular synthesis of POE2 and TxA2 is increased, and glomerular
PGE2 can alter glomerular hemodynamics.
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Methods
Materials
Bovine gamma globulin (BGG), and fluoresceinated antisera
to BOG, rat IgG and rat complement C3 were obtained from
U.S. Biochemicals (Cleveland, Ohio, USA); alkaline phospha-
tase—conjugated goat anti-rat IgG was from Cappel Laborato-
ries (Cochraneville, Pennsylvania, USA); the calcium iono-
phore, A23187, was from Calbiochem—Behring (San Diego,
California, USA); p-nitrophenyl phosphate (PNP) and 1-
ethyl—3-[3-dimethylaminopropylj-carbodiimide hydrochloride
(EDC) were from Sigma Chemical Co. (St. Louis, Missouri,
USA) and ethylenediamine was from Fisher Scientific (Pitts-
burgh, Pennsylvania, USA). 3H inulin, '4C para-amino hippur-
ate (PAH) and all radioactive ligands were obtained from New
England Nuclear (Boston, Massachusetts, USA). The antise-
rum to TxB2 was provided by Dr. William Campbell, Dallas,
Texas, USA and the anti-PGE2 was purchased from the Pasteur
Institute, Paris, France. UK-38,485 (TxA2 synthetase inhibi-
tor), was from Pfizer Inc., Groton, Connecticut, USA. Indo-
methacin was from Merck, Sharp, and Dohme (West Point,
Pennsylvania, USA) and EP-092 from Dr. R.L. Jones, Edin-
burg, Scotland.
Preparation of the cationic antigen
BGG was cationized as previously described [5, 12]. Two g
BOG was dissolved in 20 ml 0.01 M NaC1, mixed with 40 ml
ethylenediamine, and the pH adjusted to 7.0 with 2 N HC1. Four
g EDC was added and the pH was maintained at 7.0. The
mixture was left overnight at room temperature, then dialyzed
against four changes of one liter of 0.15 M NaCI over 24 hours.
Cationic BGG prepared by this procedure had an isoelectric
point (p1) in excess of 9.5; the native BGG had a range of p1
between 4.5 and 8.0, when measured by isoelectric focusing in
a thin layer agarose gel with PharmalytesR 3-10.
Experimental protocol
Sprague—Dawley rats (Zivic Miller, Allison Park, Pennsylva-
nia, USA), 150 to 200 g each, were divided into three groups.
Each received daily intravenous injections for three weeks (21
injections). The first group (control, N = 9) received 1 ml
phosphate buffered saline (PBS), the second group received 10
mg per day of native bovine gamma globulin (NBGG, N = 6),
and the third group received 10 mg per day of cationic bovine
gamma globulin (CBGG, N = 9). We wished to allow a period
of equilibration after immunization before studying glomerular
hemodynamics, and arbitrarily chose five to seven days after
the last injection when all animals were studied.
Pre-immunized model
Twenty—two Sprague—Dawley rats were pre-immunized in
the foot pads with 1 mg CBGG in complete Freund's adjuvant.
Seven days later the rats received daily intravenous antigenic
challenge with increasing doses of CBGG for six days (Day 1:
mg, Day 2: 2 mg, Day 3: 4 mg, Day 4: 6 mg, Day 5: 8 mg, Day
6: 10 mg).
Assessment of proteinuria
Rats were placed in metabolic cages, and urine was collected
for 24 hours. Urinary protein was measured by sulfosalicylic
acid—induced turbidimetry [13]. Proteinuria was assessed
weekly during the 21 day protocol, and five to seven days after
the last injection.
Hemodynamic studies
Rats were anesthetized with intraperitoneal pentobarbital (50
mg/kg) and surgery was performed on a thermocontrolled
operating table to maintain a stable body temperature. After
anesthesia, a tracheostomy was done, and the femoral and
jugular veins were exposed and catheterized. Also, the bladder
was exposed through a midline incision and catheterized for
urine collection. 3H inulin (sp. act. 250 pCi/mg) and '4C PAH
(sp. act. 230 jiCilmg) were mixed, diluted in normal saline, and
infused at a rate of 1.5 mllhr; the concentrations were adjusted
to deliver 1.6 pCi/hr 3H inulin and 1.2 jiCi/hr '4C-PAH. After an
equilibration period of 60 minutes, clearance was measured
during three periods. Each period consisted of a 20 minute urine
collection with a 100 .d blood sample drawn from the tail artery
at the midpoint of each collection. At the end of the clearance
study a blood sample was drawn from the renal vein to calculate
the percentage of PAH extracted.
Glomerular isolation and incubation
Following the clearance study, rats were killed by exsangui-
nation. Kidneys were removed, and small portions of the cortex
were taken for electron, light and immunofluorescence micros-
copy (vide infra). The remainder of the kidney tissue was placed
in ice cold PBS (0.15 M NaCI, 0.01 M sodium phosphate, pH 7.6)
and used for glomerular isolation. Glomeruli were isolated by a
differential sieving technique as previously described [14]. The
cortex was separated from the medulla and minced to a paste-
like consistency. The minced cortical paste was pressed
through a 106 jim metal sieve to remove large tubular fragments
and suspended in PBS. This suspension was triturated and
poured over a 75 jim sieve. The glomeruli were trapped on the
75 jim sieve, collected and suspended in PBS. The purity of the
glomerular preparation was assessed by light microscopy and
varied between 92 and 98%. The isolated glomeruli were
transferred to a pre-weighed siliconized glass tube and sus-
pended in Earle's Balanced Salt Solution (EBSS) with 20 mM
HEPES and 3.0 jiM calcium ionophore (A23187) at a total
volume of 1 ml. This suspension was incubated for 30 minutes
at 37°C with mild agitation. At the end of the incubation the
glomeruli were placed on ice and centrifuged at 2,500 X g for
10 minutes. The supernate was collected and frozen for
prostaglandin and thromboxane determination. The glass tube
containing the glomerular pellet was placed in a 70°C oven for
24 hours and re-weighed to determine the glomerular dry
weight.
Assay for prostaglandins and thromboxane
The radioimmunoassays for PGE2 and TxB2, the stable end
product of TxA2, were done using unextracted media. The
sensitivity and cross reactivity of the antisera were previously
described [15]. Incubation media without glomeruli were used
as blank controls.
Immunofluorescence microscopy
The cortical tissue was snap—frozen in cold 2-methylbutane
which was immersed in liquid nitrogen. Frozen tissue was
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sectioned at 4 m in a Spencer Cryostat (American Optical,
Buffalo, New York, USA) and stored at —70°C. Staining was
done as previously described [16]. Sections were layered with
goat antiserum to rat IgG (rhodamine conjugated), bovine IgG
(fluorescein conjugated) or rat complement C3 (fluorescein
conjugated), all diluted at 1:20. In randomly selected animals,
additional slides were layered with both anti-rat IgG and anti-rat
C3, or with anti-rat IgG and anti-bovine IgG for double im-
munofluorescence to enable comparison of the distribution of
these various immune reactants. Controls included sections of
rat kidney from rats with the heterologous phase (day 5) and the
autologous (day 14) phase of nephrotoxic serum nephntis [3]
and rats which had been intravenously injected with a single
dose of 3 mg CBGG. Rat C3, but not rat IgG or bovine IgG, was
present in a linear pattern in glomerular capillary wall five days
alter injection of nephrotoxic serum; fourteen days after injec-
tion of nephrotoxic serum, both rat C3 and rat IgG were present
in a linear capillary wall pattern; bovine IgG was absent. One
hour after injection of CBGG into a normal rat, there was finely
granular staining in capillary walls for bovine IgG; rat IgG and
rat C3 were absent. Thus, by immunofluorescence on known
positive and negative control tissue, the anti-sera used were
specific, and cross reactivity was not a problem. Ouchterlony
double immunodiffusion also confirmed appropriate binding
without cross reactivity. Coded sections, to prevent observer
bias, were examined microscopically (Ernst Leitz Inc.,
Wetzlar, West Germany).
Electron microscopy
Small, 1 mm portions of renal cortex were immersion-fixed in
2.5% glutaraldehyde in 0.1 M sodium cacodylate adjusted to pH
7.3. The tissue was post-fixed in 1% 0504 and embedded in
Spun's epoxy. Ultrathin 50 nm sections were cut, picked up on
uncoated nickel grids and stained with uranyl acetate and lead
citrate. Coded specimens were evaluated in a Philips 201 C
electron microscope (Philips Medical Electronics Div.,
Piscataway, New Jersey, USA) for the number and size of
electron dense deposits in subendothelial, intramembranous,
subepithelial and mesangial glomerular sites, in a manner iden-
tical to that previously described [16].
Light microscopy
Tissue was immersion—fixed in 10% formalin buffered to pH
7.5 with 0.01 M sodium phosphate for 24 hours. The tissue was
then processed through graded alcohols and xylenes and infil-
trated in molten Paraplast (Fisher Scientific, Pittsburgh, Penn-
sylvania, USA). The tissue was embedded, sectioned at 4 pm
and stained with periodic acid silver—methenamine or with
hematoxylin and eosin. Coded sections were examined in a light
microscope (American Optical, Buffalo, New York, USA). Cell
nuclei were counted in 10 randomly—selected glomeruli from
each rat, and cross—sectional glomerular area in the section
measured, using morphometric software (Bioquant, Nashville,
Tennessee, USA) in a microcomputer (Apple Computers, Sun-
nyvale, California, USA), coupled to a microscope—mounted
video camera.
Determination of serum antibody
Prior to death, a blood sample was drawn from the aorta and
antibody to bovine IgG was determined by an ELISA similar to
that previously described [16], using modifications of the tech-
nique developed by Engvall [17] and characterized by Can-
tarero, Butler and Osborne [18]. Polystyrene microtiter plates
(Cooke Engineering, Alexandria, Virginia, USA) were coated
with bovine IgG (10 tg/ml) in 0.1 M sodium carbonate, pH 9.5;
after coating, and between all subsequent steps, all wells were
washed three times in PBS. The coated plates and uncoated
control plates were "blocked" by incubation with 1% bovine
serum albumin in PBS. Samples of rat serum or a standard
pooled rat serum were incubated at room temperature for one
hour (100 l/well), serially diluted in PBS over a range from 1:10
to 1:270. One hundred s1 of a 1:100 dilution of alkaline
phosphatase—conjugated goat anti-rat IgG was added to each
well for one hour at room temperature, and the plates were
developed with 100 dIwell of 4 mg/mI PNP in glycine/NaOH
buffer pH 10.5. The reaction was followed at 410 nm in a
microplate reader (Dynatech, Inc., Alexandria, Virginia, USA)
during the 60 minute linear phase of the reaction. Amount of
antibody was determined by 0D410 at 1:10 dilution interpolated
into a semilog regression of a known standard for comparison of
antibody level. The titer was computed by extrapolating 0D410
for the serial dilutions against the number of dilutions. The titer
of each sample was the reciprocal of the dilution at the point
where the extrapolated line crossed a line 2 SD above the 0D410
developed with normal rat serum as a negative control. Geo-
metric mean titers were computed for each group. Coefficient of
variation was less than 10% throughout.
In vivo cyclo-oxygenase inhibition
Experiments were done on a group of five rats after three
weeks of CBGG injection (21-day model), and on a group of
four rats after pre-immunization and six days of daily, intrave-
nous antigenic challenge (pre-immunized model). The initial
three clearance measurements were performed as described
above, five to seven days after the last antigenic challenge. This
was followed by intravenous infusion of indomethacin, 3.0
mg/kg, over 20 minutes. The clearances were then repeated.
Indomethacin was dissolved in 0.5 M sodium carbonate, then
neutralized with 0.5 M HCI and diluted with saline.
In vivo thromboxane inhibition and receptor blockade
Experiments were performed on four rats after the animals
received three weeks of CBGG and became proteinuric. Ini-
tially, three clearance periods were done, then the rats received
the TxA2 synthetase inhibitor UK-38,485, 1.0 mg/kg i.v. over 20
minutes, followed by a 20 minute i.v. infusion of the TxA2
receptor antagonist, EP-092, 2.0 mg/kg. After completion of
both infusions a second set of clearances was determined.
UK-38,485 was dissolved in a small volume of 0.1 N NaOH,
then adjusted to pH 8.3 with 0.1 N HC1. Final dilution was made
in saline. EP-092 was dissolved in ethanol and an equimolar
amount of NaOH was added. The ethanol was then evaporated
under nitrogen, and the residue was dissolved in saline.
Experimental protocol for thromboxane synthesis inhibition
Twenty—two rats were pre-immunized with CBGG as de-
scribed above. After seven days the rats were divided into two
groups of 11 rats each. The control group received daily i.v.
CBGG for six days and 2 ml saline every 12 hours by oral


































1320 Rahman et a!
Fig. 1. Light micrographs. Representative glomeruli from age—matched control (A), NBGG-immunized (B) and CBGG-immunized (C) rats are
shown. Note the absence of cellular infiltrate or proliferation, the widely patent capillary lumina, and lack of basement membrane changes in both
rats with immune complex deposits without disease (B) and in nephrotic rats (C); both are indistinguishable from controls (A). (Hematoxylin and
eosin stain, final magnification 333 x).











NBG (6) 67.2 10.13 l0.0 1.14 6.7a 0.43
CBGG (9) 67.3 9.37 12.8 0.89 5.2 0.44
Control (9) 62.6 9.11 12.9 0.46 4.9 0.64
a Different from both control and CMBGG, P <
protected t-test from ANOVA
0.01, by Fisher's
days and UK-38,485 40 mg/kg every 12 hours by oral gavage.
UK-38,485 was dissolved in 0.1 N NaOH, then adjusted to pH
8.3 with 0.1 N HC1. Final dilutions to 4 mg/mI in the final
solution were made into saline. Proteinuria was examined at
day three and day six of intravenous antigen challenge.
Statistical analysis
All results were analyzed by Student's t-test (for 2 groups) or




The rats that received NBGG (N = 6) over 21 days developed
insignificant increments in protein excretion, 16.0 3.0 mg/24
hr, compared to control (N = 9), 9.4 0.5 mg/24 hours. In
contrast, the rats that received CBGG (N 9) developed
marked proteinuria, 86.6 18.8 mg/24 hours during the third
week of antigen injection.
Pathology
Light microscopy was identical in both sham and antigen-
injected rats and indistinguishable from normal age—matched
controls. No mesangial proliferation or cellular infiltration were
seen (Fig. 1, Table 1). The lack of cellular infiltration was a
consistent finding up to two months after the last antigen
injection. However, immunofluorescence microscopy showed





Controls NBGG CBGG UK 38,485 with saline
10.3 12 87 244 236
12 14 110 325 412
8 31 16 113 114
7.6 12 22 511 206
9 15 68 330 438




a Data are 24-hour protein excretions of six rats of 11 in each group.
These rats were maintained on treatment for six days. There was no
difference in 24-hour proteinuria between UK 38,485-treated and ne-
phrotic control animals in II rats per group observed on day three (data
not shown). Five rats in each group were sacrificed after three days of
treatment.
conspicuous differences between rats receiving CBGG and
NBGG (Fig. 2). Administration of NBGG resulted predomi-
nantly in mesangial deposits of BUG and rat IgG; however, no
complement staining was seen. The injection of CBGG induced
uniform, granular capillary—wall deposits of BGG, rat IgG, and
complement C3. None of the glomeruli from control rats
showed immunofluorescent staining for BGG, rat IgG, or C3.
Electron microscopy of glomeruli from CBGG-injected animals
showed broadening of the foot processes and numerous, regu-
larly—spaced electron—dense subepithelial deposits (Fig. 3) as
well as mesangial deposits. There was no thickening of the
capillary basement membrane and no neutrophil or monocyte
infiltration. In contrast, electron microscopy after injection of
NBGG showed numerous, small mesangial deposits and rare,
isolated subepithelial deposits, with no other abnormality evi-
dent.
Determination of serum antibody levels
By analysis of variance, there was no difference in the
amount of antibody in the sera from rats immunized for 21 days
with NBGG (mean ELISA optical density SE = 469 75,
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Fig. 2. Immunofluorescence micrographs.
Immunofluorescence micrographs
representative of rats immunized with CBGG
(left column) or NBGG (right column) are
shown. In rats immunized with CBGG, there
were granular capillary wall and mesangial
deposits of BOG (A), rat IgG (B), and rat
complement C3 (C). Rats immunized with
NBGG had purely mesangial deposits of EGG
(D) and rat IgG (E); complement C3 was not
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Fig. 3. Electron micrographs. By low power magnification (A), a glomerulus from a rat immunized with CBGG reveals numerous small to
moderate distinct electron dense deposits (arrows) in mesangium (M) and in the capillary wall. There is extensive epithelial podocyte fusion;
endothelium is intact and no leukocytic or thrombocytic infiltrate is present (final magnification 4,500x). Higher power examination (B) reveals
regularly spaced electron—dense deposits (arrowheads) are widely distributed along the subepithelial side of the glomerular basement membrane.
In most rats, focal areas of the capillary wall contain larger, coalescent epimembranous deposits (arrows). The epithelial podocytes are broadened
to form elongate syncytia; parts of only two swollen podocytes are present in this field (final magnification 32,000x). No deposits were observed
in the capillary walls of rats immunized with NBGG, or of sham immunized rats. NBGG rats did show numerous small mesangial deposits.
equivalent to 818 j.tg/ml Ab in standard serum) compared to rats
immunized for 21 days with CBGG (560 83, equivalent to
1821 g/ml Ab in standard serum); both groups of immunized
rats had approximately 30-fold increases in anti-BGG antibody
compared to normal rat sera (90.0 7.0, equivalent to <30
j.tg/ml Ab in standard serum) (P <0.01). The optical densities of
serial dilutions of sera from rats given CBGG and rats given
NBGG were linear with the number of dilutions (correlation
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coefficients ranged from 0.89 to 0.97, all P < 0.001) and
therefore the optical densities developed were linear with the
logarithm of serum concentration. Titers were computed from
the semilog regressions: the geometric mean titers were 1177
1.87 for NBGG sera and 1126 1.85 for CBGG sera; the
geometric mean titer for three normal rat sera was less than 10,
by definition.
Renal hemodynamics
Figure 4 illustrates the changes in renal hemodynamics.
Clearances were performed five to seven days after the last
antigen or sham injection. GFR was similar in all three groups
(2.3 0.22 mI/mm, N = 9 for control, 2.46 0.60, N = 5 for
NBGG and 2.69 0.23 mI/mm, N = 9 for CBGG). RPF was
significantly increased from 5.54 0.56 mi/mm for control to
8.37 0.90 mI/mm, P <0.05 after 21 daily injections of CBGG.
Therefore, the filtration fraction was reduced from 0.42 to 0.32.
RPF after administration of NBGG was 6.05 0.90 mI/mm






Fig. 6. The effect of indoinethacin on hemodynamics. The cyclooxy-
genase inhibitor, indomethacin 3 mg/kg, reduced the GFR and RPF in
rats given CBGG. Points represent mean SEM of five clearance
experiments. Before administration of indomethacin, GFR was 1.91
0.38 and RPF was 7.36 1.0 mI/mm. After indomethacin, both GFR
and RPF were decreased to 1.22 0.31 and 4.60 0.97 mI/mm,
respectively (*P < 0,05).
Glomerular production of PGE2 and TxB2
The glomerular synthesis of POE2 and TxB2 is shown in
Figure 5. There was no statistical difference in either PGE2 or
TxB2 production between control (N = 9) and NBGG (N = 6)
rats. In rats that received CBGG (N = 9), however, the
glomerular production of POE2 was increased (2.23 0.37 vs.
1.03 0.16 ng/mg glomerular dry wt for control, P < 0.01).
TxB2 increased also from 0.48 0.07 to 3.1 0.50 ng/mg
glomerular dry wt (P < 0.001), and a significant correlation (r =
0.82, P < 0.01) was found between glomerular TxB2 synthesis
and the logarithm of 24 hours protein excretion.
Cyclo-oxygenase inhibition
To determine if the increment of RPF is secondary to
increased POE2, we administered indomethacin, 3 mg/kg over
20 minutes, to five rats after they received CBGG injections for
three weeks. The results are shown in Figure 6. Before admin-
istration of indomethacin, GFR was 1.91 0.38 and RPF was
7.36 1.0 mI/mm. After indomethacin, both GFR and RPF
were significantly decreased, to 1.22 0.31 and 4.60 0.97,
respectively (P < 0.05). The decrements of GFR and RPF were
of the same magnitude (37%); therefore, filtration fraction was
unchanged. Olomerular POE2 synthesis was inhibited by 80%
to 0.39 0.19 ng/mg glomerular weight.
Thromboxane synthesis inhibition and receptor blockade
To examine the effect of increased glomerular TxA2 on renal
hemodynamics, we administered UK-38,485, a TxA2 synthesis
inhibitor, and EP-092, a TxA2 receptor blocker, to four rats
after they received CBOO for three weeks. There was no
statistical difference in either OFR or RPF before and after both
thromboxane synthetase inhibition and receptor blockade (pre-
treatment OFR was 2.2 0.42 and RPF was 8.1 0.9;
post-treatment GFR was 1.9 0.32 and RPF was 7.8 0.83).
Pre-immunized CBGG model
Proteinuria developed in 60 to 70% of the 11 untreated rats
after four intravenous injections of CBOO and in 100% of rats
























Fig. 4. Renal hemodynamics. Mean GFR (U) and RPF (D) (mi/mm)
are shown for the three groups of rats. Although there was no difference
in GFR among the groups, RPF was increased in the CBGG group, 8.37








Fig. 5. Eicosanoid synthesis. Glomerular synthesis of PGE2 () and
TxB2 (U) (ng/mg glomerular dry wt.) are indicated for control, NBGG
and CBGG groups. Significant increases in POE2 (*P < 0.01) and TxB2(** < 0.001)were observed in CBGG rats versus controls, whereas no
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Light, immunofluorescence, and electron microscopy of the
kidney was similar to rats which received three weeks of CBGG
injections. Interestingly, although the antibody level in sera
from rats pre-immunized and challenged with cationic BGG
(484 45.5, equivalent to 935 g/ml Ab in standard serum) was
not different from rats immunized for 21 days with the same
antigen (560 82.6, equivalent to 1821 g/ml Ab in standard
serum), the titers were substantially higher in sera from preim-
munized rats (>9000) than that of rats immunized for 21 days
(1126 1.85, P <0.001). Furthermore, glomeruli isolated two
to three days after six intravenous injections of CBGG showed
increased production of TxB2 (2.17 0.16 vs. control 0.48
0.07 nglmg glomerular wt, P < 0.01). PGE2 was also increased
but the increment did not reach statistical significance (1.27
0.29 vs. control 1.03 0.16 nglmg glomerular wt).
Hemodynamics and cyclooxygenase inhibition in the
preimmunized model
In rats with nephrosis induced by preimmunization and
subsequent i.v. challenge, the GFR was 1.96 0.21 and the
RPF 6.43 0.55 ml/min. The filtration fraction was therefore
0.304 0.027. Thus, GFR was no different from normal
controls (2.3 0.22 mI/mm), but was significantly less than the
mildly increased GFR (2.69 0.23 mllmin) observed in the rats
given CBGG for 21 days (P < 0.05). Likewise, the modest
increase in RPF in pre-immunized rats relative to normal
controls (5.54 0.56 mI/mm) was not significant, but was
significantly less than the RPF in the rats given 21 i.v. doses of
CBGG (8.37 0.90 mI/mm, P < 0.05). The filtration fraction in
the pre-immunized rats was decreased to an extent similar to
that observed in rats given 21 daily i.v. doses of CBGG.
After indomethacin infusion (3 mg/kg over 20 mm), the GFR
decreased to 1.65 0,17, and the RPF decreased to 5.13 0.28
mI/mm. Both the GFR and RPF were significantly decreased
(paired t's  2.6, P's < 0.05) from their pre-indomethacin
levels, to a proportionate degree. The filtration fraction re-
mained at 0.322 0.05 after indomethacin treatment. The
approximately 20% reduction in GFR and RPF by indomethacin
observed in the pre-immunized model is significantly less than
the nearly 40% reduction in these parameters observed in rats
given CBGG for 21 days after identical indomethacin treatment,
in keeping with the relatively lower RPF and PGE2 synthesis
observed in the pre-immunized model. Protein excretion before
indomethacin (0.41 0.05 mg/mm) was unchanged after indo-
methacin (0.38 0.03 mg/mm).
Thromboxane synthezase inhibition and protein excretion in
the preimmunized model
Pre-treatment with UK-38,485 in 11 preimmunized rats re-
sulted in a slight reduction in proteinuria after three days of
intravenous CBGG, but this decrement did not reach a statis-
tical significance (77.3 34 vs. control 169 43 mg/24 hr). The
difference in proteinuria disappeared after six days of CBGG
injections, despite continuous administration of the thrombox-
ane synthetase inhibitor, 80 mg/kg/day (263 66 mg protein, 24
hr for UK-38,485 treated rats, vs. 249 59 mg/24 hr for
untreated rats). At the same time, the UK-38,485 treatment was
accompanied by greater than 85% reduction in glomerular TxB2
(0.27 0.09ng/mg glomerular wt after UK-38,485 treatment vs.
2.17 0.18 ng/mg glomerular wt for the untreated).
Discussion
Previous studies implicate glomerular eicosanoids as impor-
tant mediators of glomerular injury in toxic nephrosis induced
by adriamycin [I], or in NSN glomerulonephritis [2, 3]. NSN is
characterized by leukocytic infiltration of glomeruli, which
could be the source of the eicosanoids. In the present work, we
sought to evaluate glomerular eicosanoids and their hemody-
namic role in a model of immune complex glomerulonephritis
without infiltrating leukocytes. To this end, we adapted a
previous murine model of membranous nephropathy induced
by CBGG [16] to rats.
Cationic antigens or antibodies promote granular capil-
lary—wall deposits of immune complexes. Like the active mod-
els in mice and rabbits [6, 16] and a passive in situ model in rats
[7], the immune response to chronic cationic antigen adminis-
tration elicited subepithelial deposits of BGG antigen and rat
IgG and C3 associated with heavy proteinuria in our model.
Border et al reported heavy mesangial deposits in rats given
cationized albumin, and capillary wall deposits after injection of
anionic or neutral albumin [19]. None of the rats immunized
with any form of albumin developed proteinuria in excess of 50
mg/24 hr [19]. The reason for the divergence of our model from
that of Border et al in the same strain of rat might be due to
dissimilar immune responses related to the differences in anti-
gens and immunization protocols.
Light and electron microscopic evaluation of glomeruli from
rats given CBGG showed no leukocyte infiltration. Therefore,
the enhanced synthesis of POE2 and TxA2 we observed most
probably represents production by endogenous glomerular cells
since both glomerular epithelial and mesangial cells synthesize
PGE2 and TxA2 [20, 211.
Increments of glomerular synthesis of POE2 and TxA2 were
observed only in the CBGG animals that developed proteinuria.
Enhanced glomerular synthesis of POE2 and TxA2 agrees with
previous observations of arachidonic acid metabolism in exper-
imental glomerular disease (NSN) at three to 24 hours and 14
days after immunologic injury [2, 3]. The mechanism underlying
enhanced arachidonic acid metabolism by glomerular cells is
unclear. PGE2 and TxA2 synthesis by cultured rat mesangial
cells and rabbit peritoneal macrophages is stimulated by im-
mune complexes and by activated complement [22—25]. Hence,
it is possible that deposition of immune complexes in the
glomerulus and perhaps subsequent complement activation can
stimulate synthesis of POE2 and TxA2 by glomerular mesangial
and/or epithelial cells.
The hemodynamic effect of glomerular eicosanoids appeared
to be vasodilation in both the chronically immunized and the
pre-immunized models. While all animals maintained normal
GFR, RPF was increased only in the rats given CBOG for 21
days. The modest increase in RPF in the pre-immunized rats
was significantly less than the pronounced glomerular hyper-
emia observed in rats given CBGO for 21 days, although the
decreased filtration fractions in the two groups were identical.
The increment in RPF apparently maintained normal OFR in
the rats given CBGG for 21 days. In contrast, we did not find
any alteration in glomerular hemodynamics after administration
of NBGG. Olomerular PGE2 had important vasodilatory ac-
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tions, as shown by the deleterious effect of indomethacin, a
cyclooxygenase inhibitor, on renal function. Acute administra-
tion of indomethacin, which reduced glomerular PGE2 synthe-
sis by 80%, resulted in proportionate decreases in GFR and
RPF, leaving filtration fractions unchanged, in both the 21 day
model and the pre-immunized model. As predicted from the
more modest increments in RPF and glomerular PGE2 produc-
tion in the pre-immunized model, the hemodynamic effects of
indomethacin on the pre-immunized model were quantitatively
less pronounced but qualitatively the same as in the 21 day
model.
Glomerular TxA2 was hemodynamically unimportant as dem-
onstrated by the lack of changes in RPF and GFR after
concurrent administration of both a thromboxane synthetase
inhibitor, UK-38,485, and a thromboxane receptor antagonist,
EP-092, which is a competitive inhibitor of the thromboxane
receptor in smooth muscle and platelets [26, 27]. We used doses
of these drugs previously demonstrated to be effective in
glomerular disease in rats [2, 3] and we documented an 85%
reduction in glomerular TxB2 in our rats.
These results are in agreement with the findings of Stork and
Dunn who found no increments of GFR and RPF in the
autologous phase of rat NSN after treatment with thromboxane
synthetase inhibitors (UK-38,485 and OKY-158l) and the re-
ceptor blocker EP-092, whereas indomethacin reduced both
GFR and RPF by 50% [3]. Clinical reports have also docu-
mented the deleterious effects of cyclooxygenase inhibition on
renal function in diverse types of glomerular disease. In patients
with chronic glomerulonephritis [28, 29], lupus nephritis [30]
and the nephrotic syndrome [31, 32] administration of nonste-
roidal anti-inflammatory drugs can result in marked reduction of
GFR.
The increment of glomerular TxA2 after administration of
CBGG was significantly correlated with protein excretion; this
finding has been demonstrated in other models of immune
glomerular disease [2, 33]. In the pre-immunized nephrotic rats,
TxA2 inhibition transiently reduced proteinuria at three days
but, after six days of treatment with UK-38,485, protein excre-
tion in both treated and untreated animals was identical, despite
an 85% inhibition in TxA2 synthesis. A primary, causal action of
TxA2 in proteinuria is therefore unlikely.
Our efforts to compare the effects of mesangial (NBGG)
versus capillary wall (CBGG) deposits of immune complexes on
glomerular eicosanoids and hemodynamics were complicated
by the lack of complement deposition and objective signs of
renal disease in the NBGG group. It is possible that the lack of
renal injury in the NBGG group of rats is related to the degree
of immune complex or complement deposition rather than the
exclusive deposition of complexes in the mesangium. The lack
of complement deposition in NBGG rats may also account for
lack of increments in eicosanoids or hemodynamic changes.
Mesangial cells synthesize more eicosanoids than glomerular
epithelial cells [20, 211 and are stimulated to produce increased
PGE2 by complement [22, 23]. The explanation for the absence
of complement deposition in the NBGG model may be related
to fewer immune complexes deposited, diminished access of
complement components to the mesangial area, greater catab-
olism of complement components in mesangial versus capillary
sites, or some combination of these. Different subclass distri-
bution of antibody elicited to NBGG versus CBGG may also be
a factor.
In summary, we observed that immunization of rats with
CBGG induced a proteinuric glomerular disease morphologi-
cally similar to membranous nephropathy, with concomitant
increases of glomerular eicosanoid production, apparently from
endogenous glomerular cells. Inhibition of PGE2 resulted in
reduction of both GFR and RPF, but inhibition of TxA2 had no
effect on glomerular hemodynamics or protein excretion.
Therefore, the increment in RPF is most probably due to
increased POE2, but the increment in TxA2 does not exert a
measurable vasoconstrictor effect and probably is not a com-
ponent in the pathogenesis of the proteinuria.
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